152 related articles for article (PubMed ID: 23710587)
1. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China.
Wen Y; Huang H; Huang H; Wu M; Shen K; Pan L
Climacteric; 2013 Dec; 16(6):673-81. PubMed ID: 23710587
[TBL] [Abstract][Full Text] [Related]
2. The safety of tibolone in epithelial ovarian cancer patients.
Lee KB; Lee JM; Yoon JH; Park CY
Maturitas; 2006 Sep; 55(2):156-61. PubMed ID: 16563669
[TBL] [Abstract][Full Text] [Related]
3. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of Patients with Serous Ovarian Carcinoma.
Zhang YL; Chen JH; Lu W; Li BL; Zhu QY; Wan XP
Chin Med J (Engl); 2016 Jun; 129(11):1316-21. PubMed ID: 27231169
[TBL] [Abstract][Full Text] [Related]
5. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
6. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
[TBL] [Abstract][Full Text] [Related]
7. Early stage epithelial ovarian cancers: a study of morphologic prognostic factors.
Terzi A; Aktaş IY; Dolgun A; Ayhan A; Küçükali T; Usubütün A
Pathol Res Pract; 2013 Jun; 209(6):359-64. PubMed ID: 23643734
[TBL] [Abstract][Full Text] [Related]
8. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
10. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma.
Gao Y; Liu Y; Meng F; Shang P; Wang S; Zhang Y; Sun Y; Wang Y; Wang J; Chen X
Int J Gynecol Cancer; 2016 Jan; 26(1):114-9. PubMed ID: 26512788
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study.
Gallotta V; Petrillo M; Conte C; Vizzielli G; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Carbone V; Scambia G
J Minim Invasive Gynecol; 2016; 23(5):769-74. PubMed ID: 26995493
[TBL] [Abstract][Full Text] [Related]
14. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
15. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery.
Paulsen T; Kærn J; Tropé C
Gynecol Oncol; 2011 Jul; 122(1):83-8. PubMed ID: 21435701
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy and prognosis in ovarian cancer patients.
Hein A; Thiel FC; Bayer CM; Fasching PA; Häberle L; Lux MP; Renner SP; Jud SM; Schrauder MG; Müller A; Wachter D; Strehl J; Hartmann A; Beckmann MW; Rauh C
Eur J Cancer Prev; 2013 Jan; 22(1):52-8. PubMed ID: 22694828
[TBL] [Abstract][Full Text] [Related]
18. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
19. Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study.
Bacalbasa N; Balescu I; Dima S; Popescu I
Anticancer Res; 2014 Dec; 34(12):7303-8. PubMed ID: 25503164
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.
Chang C; Chiang AJ; Wang HC; Chen WA; Chen J
Ann Surg Oncol; 2015 Nov; 22(12):3976-80. PubMed ID: 25777089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
